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Candidiasis, a well-known opportunistic
infection of AIDS patients, is the leading cause of
infectious esophagitis  (1,2). Studies show
similar prevalence of Candida esophagitis in
AIDS patients in the West (9.1% to 31%) (3-5)
and in Africa (7.3% to 27%) (6-7). In most treated
patients (80% to 100%) Candida esophagitis
recurs  after 3 months (8,9). Nevertheless, in
patients with AIDS, candidiasis generally does
not become systemic, and thus, clinical cure is
important (9). Defining the most effective
diagnostic and therapeutic approach to curing
Candida esophagitis in AIDS patients is
especially important in developing countries,
which often have limited resources.
Diagnosis of esophageal candidiasis is
usually based on the endoscopic appearance of
the typical mucosal lesions and on histopatho-
logic studies (10-12). Several western studies
have shown that the diagnosis of this disease in
AIDS patients can be made on clinical findings
alone because the positive predictive value of
esophageal symptoms as indexes of esophageal
infection is 71% to 100% (10,13,14). Such an
evaluation has not yet been made in African
AIDS patients.
Several therapeutic regimens have been
effective in treating oral and esophageal
candidiasis (8,15-23). For the past decade, oral
nystatin therapy has been considered effective in
controlling Candida esophagitis (11). In tropical
countries, the efficacy of nystatin in treating this
disease is not well known, although a recent
study in Zaire reported a cure rate of less than
10% (24). We evaluated the diagnostic accuracy
of esophageal symptoms in predicting Candida
esophagitis in Ugandan AIDS patients with oral
candidiasis and compared the effectiveness of
miconazole and nystatin in treating oral and
endoscopically proven esophageal candidiasis in
these patients.
The Study
From September 1994 to December 1995, 320
consecutive AIDS patients were observed at the
Gastroenterology Department of Hoima Hospital
in Uganda. Among them, 85 (45 women, 40 men,
mean age 27.1, standard deviation [SD] 5.3
years) fulfilled admission criteria: positive HIV
test or clinical diagnosis of AIDS and presence of
oral patchy white plaques as markers of oral
candidiasis. The district medical officer and the
hospital medical superintendent granted ap-
proval for the study, and informed consent was
obtained from each patient. Patients were
considered symptomatic if they had any of the
following symptoms: odinophagia, dysphagia, or
retrosternal burning pain.
All patients were hospitalized, and the upper
digestive tract was examined endoscopically.
The diagnosis of esophageal candidiasis was
made at the examination. All patients had the
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patients showed that esophageal candidiasis in AIDS patients with oral candidiasis
could be managed without endoscopy and biopsies. Oral lesions, especially when
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more effective than nystatin in treating esophageal candidiasis and could be a valid
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Table. Characteristics of patients participating  in the study
Mean age Sex
No. (yr) (S.D.) M/F
Oral candidiasis 85 24.0 (6.7) 32 / 53
Esophageal symptomsa 40 17 / 23
  Nystatin group 20 23.9 (6.1)   7 / 13
  Miconazole group 20 23.7 (6.6)   8 / 12
Esophageal candidiasis 77 23.7 (6.4) 27 / 50
  Nystatin group 37 24.2 (6.5) 12 / 22
  Miconazole group 40 23.4 (6.1) 15 / 28
aEsophageal symptoms are any of the following: odinophagia,
dysphagia, retrosternal burning pain.
Figure. Esophageal candidiasis treatment flow.
same spectrum of lesions: patchy white plaques,
confluent pseudomembrane, and friable mucosa.
Routine histopathologic assessment was not
performed, mainly because of cost.
Patients were randomly assigned to the
nystatin or miconazole regimen; a stratified
randomization method was used to balance
treatment groups by esophageal symptoms, age,
and sex (Table). Nystatin tablets were given at a
dose of 1,000,000 I.U. every 8 hours for 7 days
(according to Uganda Ministry of Health 1993
National Standard Treatment Guidelines), while
miconazole tablets were administered at a dose of
250 mg every 6 hours for 7 days (25). At a mean
follow-up of 7.6 days (SD 0.9), the patients
symptoms were reassessed, and the upper
digestive tract was reexamined endoscopically.
The endoscopist was blind to the treatment used.
Patients given nystatin who still had candidiasis
were placed on the miconazole regimen and
tested for candidiasis 1 week later.
Findings
Most (90.8%) (42 female, 35 male, mean age
28.0 ± 5.8 years) of the study participants had
both oral and esophageal candidiasis. Forty
(47.1%) had esophageal symptoms, and all had
esophageal candidiasis at endoscopy. Sensitiv-
ity, specificity, and the positive and negative
predictive values of esophageal symptoms as
markers of esophageal infection were 83.3%
(confidence interval [CI] 69.2 to 92.0), 100% (CI
88.3 to 100), 100% (CI 89.1 to 100), and 82.2% (CI
67.4 to 91.5), respectively.
Esophageal symptoms disappeared in 10
(27.0%) of the 37 patients in the nystatin group
and in 38 (95.0%) of 40 patients in the miconazole
group (Yates chi-square = 34.99, p <0.001). Oral
candidiasis was cured in all patients in both
groups; esophageal candidiasis was cured in 8
(21.6%) patients in the nystatin group and in 37
(92.5%) patients in the miconazole group (Yates
chi-square = 36.89, p <0.001). Of the 29 patients
who did not respond to nystatin, 27 (93.1%) were
cured with miconazole (Figure). No adverse
effects were observed in either group.
More than 90% of AIDS patients with oral
candidiasis in this study also had esophageal
candidiasis, thus confirming that such an
association is also very strong in Uganda (14,26).
A little more than half (51.9%) of 77 patients with
esophageal candidiasis also had esophageal
symptoms. Our findings and those of other
studies support the observation that esophageal
candidiasis could be suspected if oral thrush is
present, especially when esophageal symptoms
are associated (10,14,26,27). Thus, in tropical
countries, endoscopic assessment and biopsies
might best be reserved for patients who have
esophageal symptoms after receiving prolonged
antifungal treatment to confirm diagnosis of
candidiasis or to determine other infectious
causes of this symptoms (e.g., herpes simplex
virus infection, cytomegalovirus infection,
cryptosporidiosis) (2,23).
Although our study was not designed to
detect recurrence of candidiasis, esophageal
candidiasis is likely to recur in AIDS patients
within 12 months from any antifungal treat-276 Emerging Infectious Diseases Vol. 5, No. 2, MarchApril 1999
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ment; if it does, response to therapy is worse than
response to initial therapy (28). For this reason,
as well as the possibility of resistance to
miconazole (sporadic cases have been reported
[29]), more expensive azolic drugs (e.g.,
fluconazole) should be reserved for recurrences
of the disease; the disease should be treated
initially with less expensive, but more effective
drugs (e.g., miconazole).
In sum, AIDS patients with oral candidiasis
in countries similar to Uganda can be managed
without endoscopic and bioptic assessments
since oral lesions are typical and a high
prevalence of esophageal involvement is ex-
pected (with or without symptoms) (>90% of
cases in our study). In our patients, nystatin had
a very low cure rate in the treatment of
esophageal candidiasis in AIDS patients;
however, it could still play a role in the treatment
of oral candidiasis, especially in
nonimmunocompromised patients, in whom
concomitant esophageal involvement is less
common. On the other hand, miconazole, a
medium-priced azolic drug, was very effective
and could be a valid alternative to more
expensive azolic drugs in developing countries.
Acknowledgments
We thank Dr. G. Oundo, medical superintendent, and
the staff of Hoima Hospital.
This study was funded by International Service
Volunteers Association, Kampala, Uganda.
Dr. Ravera is a specialist in gastroenterology and
digestive endoscopy. A researcher at the Italian National
Health Institute, he serves as site coordinator/monitor
of the UNAIDS PETRA study at Nsambya Hospital,
Kampala, Uganda. His research interests include gas-
troenterology, endoscopy, infectious diseases, and HIV/
AIDS.
References
    1. Wilcox CM, Karowe MW. Esophageal infections:
etiology, diagnosis and management. Gastroenterologist
1994;2:188-206.
    2. Lopez Dupla M, Mora Sanz P, Pintado Garcia V,
Valencia Ortega E, Uriol PL, Khamashta MA, et al.
Clinical, endoscopic, immunologic and therapeutic
aspects of oropharyngeal and esophageal candidiasis in
HIV infected patients: a survey of 114 cases. Am J
Gastroenterol 1992;87:1771-6.
  3. Sirera G, Clotet B, Romeu J. Incidence of opportunistic
infections and malignancies in AIDS patients from
Barcelona according to patients risk behaviour. VII
International Conference on AIDS, Florence Jun 16-21,
1991; M.B.2459 [abstract].
    4. Heise W, Arasteh K, Mostertz P. Gastrointestinal
manifestations in AIDS. Endoscopic, histological and
microbiological aspects. VII International Conference
on AIDS, Florence Jun 16-21, 1991:2227 [abstract].
  5. Scevola D. Apparato gastrointestinale. In: Dianzani F,
editor. Il libro italiano dellAIDS. Milano: Mc Graw-Hill;
1994. p. 305-12.
  6. Howlett WP, Nkya WM, Mmuni KA, Missalek WR.
Neurological disorders in AIDS and HIV disease in the
northern zone of Tanzania. AIDS 1989;3:289-96.
  7. Colebunders R, Latif AS. Natural history and clinical
presentation of HIV-1 infection in adults. AIDS 1991;5
Suppl 1:S103-12.
  8. Smith DE, Midgley J, Allan M, Connolly GM, Gazzard
B. Itraconazole versus ketoconazole in the treatment of
oral and oesophageal candidiasis in patients infected
with HIV. AIDS 1991;5:1367-71.
    9. Laine L, Bonacini M. Esophageal disease in HIV
infection. Arch Intern Med 1994;154:1577-82.
10. Connolly GM, Hawkins D, Harcourt-Webster JN,
Parsons PA, Husain OA, Gazzard BG. Oesophageal
symptoms, their causes, treatment and prognosis in
patients with the acquired immunodeficiency
syndrome. Gut 1989;30:1033-9.
11. Mathieson R, Dutta SK. Candida esophagitis. Dig Dis
Sci 1983;28:365-70.
12. Kodsi BE, Wickremesinghe PC, Kozinn PJ, Iswara K,
Golberg PK. Candida esophagitis: a prospective study of
27 cases. Gastroenterology 1976;71:715-9.
13. Bonacini M, Young T, Laine L. The causes of esophageal
symptoms in human immunodeficiency virus infection.
A prospective study of 110 patients. Arch Intern Med
1991;151:1567-72.
14. Bianchi Porro G, Parente F, Cernuschi M. The diagnosis
of oesophageal candidiasis in patients with the acquired
immune deficiency syndrome: is endoscopy always
necessary? Am J Gastroenterol 1989;84:143-6.
15. Pons V, Greenspan D, Debruin M. Therapy for
oropharyngeal candidiasis in HIV infected patients: a
randomized, prospective multicenter study group. Journal
of Acquired Immune Deficiency Syndrome 1993;6:1311-6.
16. Greenspan D. Treatment of oropharyngeal candidiasis in
HIV positive patients. J Am Acad Dermatol 1994;31:S51-5.
17. Hernandez Sampelayo T. Fluconazole versus
ketoconazole in the treatment of oropharyngeal
candidiasis in HIV infected children multicenter study
group. Eur J Clin Microbiol Infect Dis 1994;13:340-4.
18. Gil A, Lavilla P, Lopez Dupla M, Valencia E, Pintado V,
Khamashta M, et al. Treatment of esophageal
candidiasis with fluconazole in acquired
immunodeficiency syndrome. Comparative study of 2
therapeutic schemes. Med Clin (Barc) 1992;98:612-7.
19. Berger TG. Treatment of bacterial, fungal and parasitic
infections in the HIV infected host. Seminar in
Dermatology 1993;12:296-300.
20. Sutton FM, Graham DY, Goodgame RW. Infectious
esophagitis. Gastrointest Endosc Clin N Am 1994;4:713-29.
21. Soubry R, Clerinx J, Banyangiliki V. Comparison of
itraconazole oral solution and fluconazole capsules in
the treatment of oral and esophageal candidiasis in HIV
infected patients. Preliminary results. VII International
Conference on AIDS, Florence 16-21 Jun, 1991: M.B.
2201 [abstract].277 Vol. 5, No. 2, MarchApril 1999 Emerging Infectious Diseases
Dispatches
22. De Wit S. Comparison of fluconazole and ketoconazole
for oropharyngeal candidiasis in AIDS. Lancet
1989;1:746-8.
23. Laine L, Dretler RH, Conteas CN, Tuazon C, Koster
FM, Sattler F, et al. Fluconazole compared with
ketoconazole for the treatment of candida esophagitis
in AIDS. A randomized trial. Ann Intern Med
1992;117:655-60.
24. Nyst MJ, Perriens JH, Kimputu L, Lumbila M, Nelson
AM, Piot P. Gentian violet, ketoconazole and nystatin in
oropharyngeal and esophageal candidiasis in Zairean
AIDS patients. Annales  de la Societé Belge de
Médecine Tropicale 1992;72:45-52.
25. Grahame-Smith DG, Aronson JK. Oxford textbook of
clinical pharmacology and drug therapy. 2nd ed. New
York: Oxford University Press Inc.; 1992. p. 559.
26. Raufman JP, Rosenthal LE. Oral candidiasis as a
marker for esophageal candidiasis in the acquired
immunodeficiency syndrome. Ann Intern Med
1986;104:54-8.
27. Bassetti D, Canessa A. Micosi. In: Ferdinando
Dianzani, editor. Il libro italiano dellAIDS. Milano: Mc
Graw-Hill; 1994. p. 224-8.
28. Parente F, Cerruschi M, Rizzardini G, Lazzarin A,
Valsecchi L, Bianchi Porro G. Opportunistic infections
of the esophagus not responding to oral systemic
antifungals in patients with AIDS: their frequency and
treatment. Am J Gastroenterol 1991;86:1729-34.
29. Holt RJ, Azmi A. Miconazole resistant candida. Lancet
1978;1:50-1.